- Home
- ECPG vs DYN Comparison
ECPG vs DYN Comparison
Compare ECPG & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECPG
- DYN
- Stock Information
- Founded
- ECPG 1998
- DYN 1984
- Country
- ECPG United States
- DYN United States
- Employees
- ECPG N/A
- DYN N/A
- Industry
- ECPG Finance Companies
- DYN Medicinal Chemicals and Botanical Products
- Sector
- ECPG Finance
- DYN Health Care
- Exchange
- ECPG Nasdaq
- DYN Nasdaq
- Market Cap
- ECPG 806.1M
- DYN 848.8M
- IPO Year
- ECPG 1999
- DYN 2020
- Fundamental
- Price
- ECPG $40.51
- DYN $11.41
- Analyst Decision
- ECPG Strong Buy
- DYN Strong Buy
- Analyst Count
- ECPG 3
- DYN 12
- Target Price
- ECPG $62.67
- DYN $47.00
- AVG Volume (30 Days)
- ECPG 354.2K
- DYN 2.9M
- Earning Date
- ECPG 05-07-2025
- DYN 05-08-2025
- Dividend Yield
- ECPG N/A
- DYN N/A
- EPS Growth
- ECPG N/A
- DYN N/A
- EPS
- ECPG N/A
- DYN N/A
- Revenue
- ECPG $1,380,750,000.00
- DYN N/A
- Revenue This Year
- ECPG $21.62
- DYN N/A
- Revenue Next Year
- ECPG $10.12
- DYN N/A
- P/E Ratio
- ECPG N/A
- DYN N/A
- Revenue Growth
- ECPG 11.49
- DYN N/A
- 52 Week Low
- ECPG $26.45
- DYN $6.36
- 52 Week High
- ECPG $51.77
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- ECPG 66.74
- DYN 55.69
- Support Level
- ECPG $32.27
- DYN $9.17
- Resistance Level
- ECPG $36.32
- DYN $12.47
- Average True Range (ATR)
- ECPG 1.55
- DYN 0.96
- MACD
- ECPG 0.90
- DYN 0.13
- Stochastic Oscillator
- ECPG 92.47
- DYN 67.88
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.